Therapeutic Area: Oncology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2020
This is a Phase I-II study to determine the recommended dose andnefficacy of lurbinectedin in combination with atezolizumab (Roche)nin patients with advanced Small Cell Lung Cancer.